Pulmonary vascular dysfunction in ARDS Pathophysiology and therapeutic implications
Abstract
Pulmonary vascular dysfunction is increasingly recognized as a clinically important component of acute respiratory distress syndrome (ARDS). Beyond alveolar epithelial injury, ARDS involves endothelial and alveolar-capillary barrier disruption, dysregulated hypoxic pulmonary vasoconstriction, thrombo-inflammatory activation, microvascular thrombosis, pulmonary vascular remodeling, increased pulmonary vascular resistance, and impaired right ventricle pulmonary circulation coupling. Together, these abnormalities aggravate ventilation perfusion mismatch, impair gas exchange, increase right ventricular afterload, and contribute to hemodynamic instability and adverse clinical outcomes. This review synthesizes current understanding of these mechanisms, critically evaluates pulmonary vascular-targeted interventions according to the strength of available evidence, and considers the clinical implications of biological and physiological heterogeneity in ARDS. Lung-protective ventilation remains the foundation of ARDS management, and early prolonged prone positioning improves outcomes in appropriately selected patients with moderate-to-severe disease. In addition to limiting lung injury and improving oxygenation, these strategies may reduce pulmonary vascular stress and right ventricular afterload. Inhaled pulmonary vasodilators can produce transient improvements in oxygenation or pulmonary hemodynamics, but no survival benefit has been established. Anticoagulant and fibrinolytic…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.